Viewing Study NCT07206056


Ignite Creation Date: 2025-12-24 @ 11:24 PM
Ignite Modification Date: 2025-12-25 @ 9:10 PM
Study NCT ID: NCT07206056
Status: RECRUITING
Last Update Posted: 2025-11-25
First Post: 2025-09-17
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Sponsor: Novartis Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module